{"id":"low-immunogenic-interferon-beta-1a","safety":{"commonSideEffects":[{"rate":"40-60","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"30-50","effect":"Injection site reactions"},{"rate":"20-30","effect":"Headache"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"5-15","effect":"Leukopenia"},{"rate":"5-10","effect":"Depression"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon-beta-1a binds to interferon-beta receptors on immune cells, triggering intracellular signaling cascades that enhance natural killer cell activity, increase antiviral and anti-inflammatory cytokine production, and shift T-cell differentiation toward regulatory phenotypes. The 'low immunogenic' formulation is designed to minimize the formation of neutralizing antibodies against the interferon-beta protein, thereby maintaining therapeutic efficacy over time.","oneSentence":"Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:24.050Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00493077","phase":"PHASE4","title":"Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy","status":"COMPLETED","sponsor":"Biogen","startDate":"2004-05","conditions":"Multiple Sclerosis","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avonex"],"phase":"marketed","status":"active","brandName":"low immunogenic interferon-beta-1a","genericName":"low immunogenic interferon-beta-1a","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low immunogenic interferon-beta-1a activates interferon-beta signaling pathways to modulate immune responses and reduce inflammation in autoimmune diseases. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}